iPS Cells & Regenerative Medicine– category –
-
iPS Cells & Regenerative Medicine Weekly Report October 11, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report October 11, 2026 (PDF) — Download Weekly Report October 11, 2026 (PDF) — DownloadDownload 🎙 Podcast October 1... -
Daraxonrasib: First RAS inhibitor FDA approval specs for 2026
American Association for Cancer Research (AACR) USA Overview The FDA granted several oncology approvals in Q3 2026, including the groundbreaking approval of Daraxonrasib (Rasonque), the first RAS inhibitor for pancreatic cancer. Addition... -
3D Bioprinting: Multi-layered tumor organoid specs for 2026
BIOENGINEER.ORG USA Overview Advances in 3D bioprinting have enabled the creation of multi-layered tumor organoid models that accurately replicate vascular structures, stromal compartments, and tumor-stroma interactions. This novel model... -
Aglatimagene: Candel Therapeutics NSCLC Phase 2a 2026 roadmap
Trefis USA Overview Candel Therapeutics announced compelling Phase 2a clinical trial results for its investigational non-small cell lung cancer (NSCLC) therapy, aglatimagene besadenovec, demonstrating a median overall survival (OS) of 24... -
3D Bioprinting: Tsinghua University vascular organoid specs
Scienmag China Overview Researchers at Tsinghua University reported in BMC Medicine that 3D bioprinted human vascular organoid sheets effectively form functional vascular networks and restore blood flow in ischemic limbs. These sheets in... -
FAYUVI: Ultragenyx AAV9 gene therapy FDA approval and specs
DeciBio USA Overview Ultragenyx's AAV9 gene therapy FAYUVI (rebisufligene etisparvovec-hopf) has gained full FDA approval for pediatric patients with Sanfilippo Syndrome Type A (MPS IIIA), marking the first gene therapy approved for this... -
Lonvo-z: Intellia Therapeutics’ FDA approval for CRISPR therapy
Vertex AI Search (Biotech News Outlet) USA Overview Intellia Therapeutics' in vivo CRISPR gene therapy, lonvoguran ziclumeran (lonvo-z), has received Biologics License Application (BLA) approval from the U.S. FDA for the treatment of her... -
Sartorius Eveo: Cell therapy costs cut 90% to under $40,000
Onyx Newsroom Germany Overview Sartorius announced at the Cell & Gene Meeting on the Mesa that its automated Eveo Cell Therapy Platform can reduce cell therapy manufacturing costs to under $40,000 per patient. This closed system inte... -
VIPR system: Jennifer Doudna’s discovery of CRISPR ancestor
The Times of India India Overview A research team led by Nobel laureate Jennifer Doudna at the Innovative Genomics Institute (IGI) has discovered the 'VIPR system' in viruses, which utilizes a previously unknown 'gapped' DNA coding strat... -
Sanfilippo Syndrome Type A: FDA approves first gene therapy
Vertex AI Search (Neurology News Outlet) USA Overview The U.S. FDA has approved a gene therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA), a devastating childhood dementia characterized by progressive neurodegeneration. ...
